Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Clinical Features and Outcomes of Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified, Treated with CHOP-Based Regimens. (PubMed, Cancers (Basel)) - "All patients received CHOP or CHOP-like regimens as the initial treatment, with three patients undergoing complete lesion resection before chemotherapy, seven patients receiving treatment combined with chidamide (tucidinostat), two patients receiving treatment combined with brentuximab vedotin, two patients receiving treatment combined with mitoxantrone liposomes (Lipo-Mit), three patients receiving treatment combined with radiotherapy, and two patients receiving ASCT after the first-line treatment. pcPTCL-NOS is an aggressive but poorly characterized lymphoma that may require early and active systemic treatment. However, for patients with T1 tumors, reducing the intensity of treatment with CHOP should be appropriately considered."

IO biomarker • Journal • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CD20 • CD4 • CD8

ACIMTAMIG (AFM13) IN COMBINATION WITH ALLONK® (AB-101) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM THE DOSE FINDING PHASE OF THE LUMINICE-203 PHASE 2 STUDY (EHA 2025) - P2 | "Patients have exhausted standard of care therapies, including chemotherapy, brentuximab vedotin and PD-1 inhibitors. The combination of acimtamig and AlloNK® therapy demonstrates promising efficacy and a manageable safety profile, offering a potential benefit to patients with R/R cHL who have exhausted standard-of-care treatments"

Clinical • Combination therapy • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • FCGR3A • TNFRSF8

Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203). (ASCO 2025) - P2 | "All pts in the study were heavily pretreated with chemotherapy, brentuximab vedotin and PD-1 inhibitors; median (range) prior treatment lines was 4.5 (2–13), including previous stem cell transplant in 14 (58%) pts. Acimtamig in combination with AlloNK shows promising efficacy with a well-managed safety profile with the potential to address an unmet need in pts with R/R HL who have exhausted standard-of-care treatment options. Efficacy results of acimtamig plus AlloNK in pts with R/R HL."

Combination therapy • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • FCGR3A • TNFRSF8

BV-ICE PROTOCOL IN THE TREATMENT OF RELAPSES OF CLASSICAL HODGKIN'S LYMPHOMA BEFORE ALLO-HSCT (EHA 2025) - "The standard treatment for this group of patients includes new monoclonal antibodies, such as brentuximab vedotin (BV) and PD-1 inhibitors, followed by allogeneic HSCT (allo-HSCT)...Studies show that the use of BV as pretransplantation therapy can improve outcomes after allo-HSCT compared with nivolumab, which is more likely to cause various immune complications...Only 1 patient had an acute graft-versus-host disease with skin lesions, refractory to steroids, requiring effective 2nd-line therapy with ruxolitinib... BV-ICE can be an effective treatment protocol prior to allo-HSCT with minimal toxicity in patients with relapses after auto-HSCT and a refractory course of cHL. The study is continuing at the moment."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Classical Hodgkin Lymphoma • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Oncology • Thrombocytopenia • CD34

A Review of NICE UK Submissions for Antibody-Drug Conjugates in Oncology (ISPOR 2025) - "All of these ADCs were assessed by NICE from inception to 2024 12 FDA-approved ADCs were identified: Trastuzumab emtansine, Trastuzumab deruxtecan, Sacituzumab govitecan, Inotuzumab ozogamicin, Polatuzumab vedotin, Loncastuximab tesirine, Tisotumab vedotin, Enfortumab vedotin, Mirvetuximab soravtansine-gynx, Belantamab mafodotin-blmf, Gemtuzumab ozogamicin, and Brentuximab vedotin. In conclusion, ADCs have revolutionized cancer treatment with their targeted delivery and significant therapeutic benefits. The evolution of ADCs since 2000 highlights their potential in both refractory and early-stage diseases. Continued advancements in ADC design and technology promise even greater therapeutic efficacy."

NICE • Review • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Breast Cancer • Cervical Cancer • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor • Urothelial Cancer

Concomitant treatment with systemic and intralesional brentuximab for resistant CD30+ mycosis fungoides lesions. (PubMed, Eur J Dermatol) - No abstract available

Journal • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • TNFRSF8

Comparative outcomes following treatment with mogamulizumab versus brentuximab vedotin for mycosis fungoides or Sézary syndrome (SID 2025) - "However, there was an increased risk of lymphopenia (HR, 1.50; 95% CI, 1.14-1.97; P=.008) and dermatitis (HR, 1.65; 95% CI 1.09-2.50; P=.03) with mogamulizumab. Our data suggest a reduced risk of hospitalization and serious adverse events in MF/SS patients treated with mogamulizumab compared to brentuximab vedotin, possibly related to off-target effects associated with the cytotoxic agent in brentuximab vedotin."

Late-breaking abstract • Cardiovascular • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Mycosis Fungoides • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain • Respiratory Diseases • Septic Shock • Sezary Syndrome • CCR4 • TNFRSF8

Single-cell RNA sequencing informs enhanced antitumor immunity after brentuximab vedotin and combination strategy in mycosis fungoide (SID 2025) - "Mycosis fungoides with large-cell transformation (MF-LCT) has a poor prognosis and lacks effective therapies. Combining BV with BCL2 inhibitor, venetoclax, showed promising synergistic effect in CD30+ cutaneous T cell lymphoma cell lines. These findings highlight the comprehensively enhanced antitumor immunity after BV beyond its cytotoxicity and inspires potential combination with venetoclax to overcome the drug resistance."

Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma • ABCB1 • CD8 • CTLA4 • IFNA1 • IFNG • IL13 • IL4 • TNFRSF8

PD-1-BASED SALVAGE THERAPY FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER REAL-WORLD ANALYSIS (EHA 2025) - "E.g., P-GVD (Pembrolizumab, Gemcitabine, Vinorelbine, liposomal Doxorubicin) achieved CR rates of up to 95% with unprecedented PFS rates after consecutive HD/ASCT (Moskowitz et al., JCO 2021), suggesting a paradigm shift in r/r cHL...Patients received one of the following salvage regimens: (I) Pembrolizumab or Nivolumab mono (n=7), (II) N-ICE (Nivolumab, Ifosfamide, Carboplatin, Etoposide) (n=1), (III) P-ICE (Pembrolizumab, Ifosfamide, Carboplatin, Etoposide) (n=3), (IV) P-GVD (n=29), or (V) Nivolumab or Pembrolizumab + Brentuximab vedotin (n=3).The overall response rate (ORR) to salvage was 92.5%, with 47.5% achieving complete response (CR), 45% partial response (PR), and 7.5% with stable disease (SD) (40 evaluable patients)... Our findings provide real-world evidence on the effectiveness of anti-PD1-based salvage regimens followed by intensive consolidation at European academic centers. Albeit the previously reported high CR rates after anti-PD1-based salvage..."

Clinical • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), the NCCN Drugs & Biologics Compendium (NCCN Compendium), the NCCN Radiation Therapy Compendium, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC) for Pediatric Hodgkin Lymphoma, Version 1.2025. (NCCN)

NCCN guideline • Childhood Hodgkin Lymphoma

BRENTUXIMAB VEDOTIN AND CHECK POINT INHIBITORS COMBINATION THERAPY IN HEAVELY PRE-TREATED RELAPSED REFRACTORY HODGKIN'S LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE ANALYSIS (EHA 2025) - "Background: Patients with refractory and relapsed Hodgkin Lymphoma (R/R HL) who have failed multiple lines of therapy represent a clinical and therapeutic challenge due to limited effective treatment particularly in patients who are ineligible or who decline autologous hematopoietic stem cell transplantation (ASCT).Single agents Brentuximab Vedotin (BV) and immune inhibitors check points (CPI: Pembrolizumab, Nivolumab) have shown a significant improvement of the treatment outcome in this context.The combination of BV Nivolumab has been explored, in phase 1/2 study, as first salvage therapy; it was associated with an ORR of 82% and a CR rate of 61%.In view of these results, we conduct a retrospective analysis of BV and CPI combination as salvage treatment in heavily pre-treated R/R HL patients...The median follow up time was 9.1 (3.27 - 13.7) months.The over rate of response was 77.7% (14 patients), a CMR was achieved from eight (44.4%) patients: 4 patients after 2 cycles..."

Combination therapy • Retrospective data • Bone Marrow Transplantation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Oncology • Pain

Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab. (ASCO 2025) - P2 | " In SGN35-027 (NCT03646123) Part C study, patients with stage I or II cHL without bulky disease (N=154) received brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) intravenously on days 1 and 15 of each 28-day cycle. ctDNA was detectable in majority of patients with early-stage cHL at baseline, and higher levels are associated with increased disease burden. Treatment with AN+AD reduced ctDNA levels, with ctDNA becoming undetectable by EOT in all patients. In some patients, decline in ctDNA levels was observed earlier than responses observed through imaging, suggesting that ctDNA clearance may be an early indicator of treatment response."

Circulating tumor DNA • Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mantle Cell Lymphoma • Oncology

A SURVIVAL UPDATE ON A PHASE II TRIAL USING CONVENTIONAL CHEMOTHERAPY PLUS NIVOLUMAB IN ADVANCED STAGE HODGKIN DISEASE (HD) (EHA 2025) - "Background: Patients with advanced stages III,IV HD can be cured in 75-80% of cases using the conventional ABVD (doxorubicin+ bleomycin+ vinblastine + Dacarbazine), however; the minority of patients still challenging in term of progression during treatment or resistance to chemotherapy. The addition of Brentuximab vedotin can have a synergistic effect to the backbone chemotherapy AVD. Addition of Nivolumab from the very beginning can modulate the cancer microenvironment through activation of CD8 and triggering the immunologic function. This combination seems to be promising in the category of patients presenting with an advanced stage high risk score HD patients"

Metastases • P2 data • Hematological Disorders • Hodgkin Lymphoma • Neutropenia • Oncology • Pain • CD8

CHECKPOINT INHIBITORS SHOW HIGH RESPONSE RATE IN RELAPSED OR REFRACTORY GRAY ZONE LYMPHOMAS (EHA 2025) - "Frontline therapy included R-CHOP (11), R-CHOEP (1) and R-DA-EPOCH (1), with a CR rate of 31%. Five patients were treated with pembrolizumab and 8 with nivolumab (12 in third line and 1 in fourth line). In 8 cases PD-1 inhibitor was administered in combination with Brentuximab (BV)... In chemorefractory GZL cases, CPI offered high CR rates, particularly when combined with BV, and with manageable toxicity, allowing most patients to proceed to stem cell transplantation."

Checkpoint inhibition • B Cell Lymphoma • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER CHECKPOINT INHIBITORS IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: A RETROSPECTIVE ANALYSIS OF THE EBMT-LWP (CHECK-AUTO STUDY) (EHA 2025) - "However, novel therapies, including brentuximab vedotin (BV) and checkpoint inhibitors (CPI), have evolved treatment paradigms, allowing more patients to undergo ASCT...CPI was administered in the 3rd or later salvage line in 73.3% (nivolumab 55.2%, pembrolizumab 43.1%), with 85.3% receiving CPI as the last therapy pre-ASCT... This study demonstrates superior PFS outcomes in heavily pretreated R/R cHL patients receiving CPI followed by ASCT compared to historical data. Disease status at the time of ASCT remains the most important risk factor for relapse and shorter PFS. Considering recent evidence on CPI efficacy in first-line failures, earlier integration of CPI in pre-ASCT settings is supported."

Checkpoint inhibition • Retrospective data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Oncology • Transplantation

A REAL WORLD STUDY OF EFFICACY AND SAFETY OF BRENTUXIMAB VEDOTIN ALONE OR IN COMBINATION WITH OTHER DRUGS IN RELAPSED REFRACTORY PERIPHERAL T CELL LYMPHOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS (EHA 2025) - "One study was combination BV with nivolumab. This review suggested that BV alone or in combination with other drugs improved the response and survival rates in PTCL patients and was associated with tolerable adverse effects. The real world data about efficacy and safety were similar to the pivotal study. Further long term observational multicenter study is needed to evaluate longer follow up regarding the efficacy and safety."

Combination therapy • Real-world • Real-world evidence • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology • Pain • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with <10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study. (ASCO 2025) - P2 | "The combination of BV plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) was effective in pts with PTCL with CD30 ≥10%. As a frontline therapy, A+CHP demonstrated clinically meaningful efficacy in pts with non-sALCL PTCL regardless of CD30 expression, with a safety profile consistent with the label."

Clinical • P2 data • Anemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology • Peripheral T-cell Lymphoma • Systemic Anaplastic Large Cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Real-world evaluation of treatment patterns and clinical outcomes among patients with primary mediastinal large B-cell lymphoma treated with brentuximab vedotin (BV)–based treatment options in China. (ASCO 2025) - "12 patients received first-line treatment with BV in combination with R-CHOP-like regimen. This real-world study explored the patterns and clinical efficacy of BV-based regimens for PMBCL in China. Our results show that BV-based regimens for patients with CD30-positive PMBCL demonstrate good efficacy and safety in real-world settings. This result needs to be confirmed in a larger cohort."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Hepatology • Large B Cell Lymphoma • Leukopenia • Liver Failure • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain • Primary Mediastinal Large B-Cell Lymphoma • TNFRSF8

Black patients with cutaneous T-cell lymphoma (CTCL) and their likelihood to receive novel agents: A retrospective cohort analysis. (ASCO 2025) - "The introduction of novel therapies such as mogamulizumab and brentuximab vedotin (BV) for the treatment of CTCL have demonstrated improved survival compared to standard therapies...Systemic therapies were divided into three groups: standard chemotherapy (single agent or multi agent), biologics (interferon, retinoids, extracorporeal photopheresis, and oral methotrexate), and novel agents (mogamulizumab, BV, and clinical trials)... Receipt of novel agents was associated with improved survival. Black patients were less likely to receive novel agents when matched for age and disease stage. These findings suggest that treatment patterns, such as the receipt of novel agents, could play a role in the racial differences in clinical outcomes in CTCL."

Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

ALK-positive anaplastic large cell lymphoma: Statistics and survival trends. (ASCO 2025) - "ALK+ ALCL is chemotherapy responsive, and CHOP, CHOEP (CHOP+etoposide) or BV-CHP (brentuximab instead of vincristine) are the popular drug combinations used. ALK+ ALCL is a rare malignancy that favors male gender, and Caucasian race. Our analysis revealed superior survival outcomes associated with younger age, female sex, Asian/Pacific Islander origin, connective tissue involvement, unilateral and loco-regional disease, and treatment involving either surgery or non-surgical options, specifically chemotherapy. This is the first study to our knowledge to establish association of ALK+ ALCL to income, showing higher survival with increasing income bracket."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • NPM1

Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium's phase 2 study cHOD17 (NCT03755804). (ASCO 2025) - P2 | "Funded by Supported by Seagen Inc, which was acquired by Pfizer in December 2023 Clinical Trial Registration Number: NCT03755804 Background: The AEPA/CAPDac (brentuximab vedotin, etoposide, prednisone, doxorubicin [cumulative dose = 160mg/m2], cyclophosphamide, vincristine, prednisone, and dacarbazine) regimen results in excellent EFS and OS rates for pediatric cHL but resulted in 65% of patients requiring RNRT using metabolic and anatomic response criteria. A metabolic-only response assessment in the AEPA-CAPDac regimen results in high rates of omission of consolidative RT and glucocorticoids while limiting cumulative anthracycline exposure and maintaining excellent 2-year EFS of 94.7% and OS of 100%."

Clinical • P2 data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Oncology • Pain • Pediatrics • TNFRSF8

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=55 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: May 2025 ➔ May 2026 | Trial primary completion date: May 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Mesothelioma • Oncology • Solid Tumor • TNFRSF8

Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naive metastatic head and neck squamous cell carcinoma (HNSCC). (ASCO 2025) - P2 | "BV + pembro demonstrated promising clinical efficacy with a safety profile consistent with each individual agent in pts with tx-naive metastatic HNSCC with PD-L1 CPS ≥1. Biomarker analyses support the hypothesized immunomodulatory mechanism of action of BV + pembro. These encouraging data are consistent with prior findings in PD-1–refractory NSCLC and melanoma and support continued investigation of CD30-directed ADCs + anti–PD-1 therapy in solid tumors."

Clinical • IO biomarker • Metastases • P2 data • Fatigue • Head and Neck Cancer • Hematological Disorders • Lung Cancer • Melanoma • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

FRONTLINE BRENTUXIMAB VEDOTIN AND CHP IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH (EHA 2025) - P2 | "The combination of BV plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) was effective in patients with peripheral T-cell lymphoma (PTCL) with CD30 ≥10%. As a frontline therapy, A+CHP demonstrated clinically meaningful efficacy in patients with non-sALCL PTCL regardless of CD30 expression, with a safety profile consistent with the label."

Clinical • Anemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology • Peripheral T-cell Lymphoma • Systemic Anaplastic Large Cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parameters Evaluated by a Novel Tool Named TORCH. (PubMed, Bioconjug Chem) - "During the past decade, antibody-drug conjugates (ADCs) have emerged as new drugs in cancer therapy with 15 ADCs already approved such as Kadcyla, Enhertu, and Adcetris. When conjugated to an antibody, the TORCH molecule allows one to gain valuable insights on the internalization and drug release of ADCs. While we cannot exclude the influence of other factors such as receptor recycling, we have found that the receptor density is directly related to the amount of payload released intracellularly, meaning that the internalization per receptor is very similar for all investigated antibodies and cell lines."

Journal • Oncology • CTSB • CTSS